AstraZeneca cancer drug approved by US FDA

AstraZeneca cancer drug approved by US FDA

16 January 2018

The U.S. Food and Drug Administration has approved the expanded use of AstraZeneca Plc’s cancer drug Lynparza. The new approval is for use in patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.

Lynparza was developed under a global strategic oncology collaboration with Merck. The drug belongs to a new class of medicines known as PARP inhibitors and is the first to be approved to treat breast cancer. PARP inhibitors prevent cancer cells from fixing problems in their DNA. Lynparza has been on the market since 2014 for ovarian cancer.

Read the full press release.

Partners Robert Watson and Nick Sutcliffe have worked on the IP portfolio relating to Lynparza since its discovery by KuDOS Pharmaceuticals in 2003.